18 Nov EraGen announces licensing agreement with San Diego biotech
MADISON – EraGen Biosciences Inc., a Madison, Wisconsin based biotechnology firm, has entered into a strategic partnership and licensing agreements with San Diego-based, Illumina that will give each firm access to the other’s technology.
EraGen is a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market. Under the licensing agreement with llumina Inc., a global company that develops, manufactures and markets integrated systems for analysis of genetic variation and biological function, EraGen will have access to Illumina’s BeadXpress screening platform for the continued development and commercialization of clinical testing systems using EraGen’s MultiCode-PLx technology. The partnership will help EraGen expand its commercial product line.
“We look forward to seeing the delivery of innovative solutions through the combination of Illumina and EraGen technologies,” Greg Heath, senior vice president and general manager of Illumina’s diagnostic division, said in a news release. “We view this agreement as a first step toward advancing health care through leading-edge molecular tools.”